Samuel A. Bozzette

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19”.

Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

medRxiv(2022)10.1101/2022.09.22.22280245

N/A

0.464DataRank · unranked

9 citations

Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez +38 more

The importance of event rates for clinical site effects in multicenter trials

Controlled Clinical Trials(1998)10.1016/s0197-2456(98)80144-x

N/A

0DataRank · unranked

0 citations

Dennis O. Dixon, Martin McIntosh, Jeffrey M. Albert, Samuel A. Bozzette, Steven M. Schnittman +2 more

Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia

International Journal of Infectious Diseases(2024)10.1016/j.ijid.2024.107168

N/A

0DataRank · unranked

4 citations

J. Wang, Kevin J. Anstrom, Lisa M. LaVange, Jun Wen, Samuel A. Bozzette +2 more

Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)

CHEST Critical Care(2024)10.1016/j.chstcc.2024.100095

N/A

0DataRank · unranked

0 citations

Miloni Shah, Tatyana Der, Derek D. Cyr, Hussein R. Al‐Khalidi, Christopher J. Lindsell +10 more

Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis

UNC Libraries(2024)10.17615/stmd-4q47

N/A

0DataRank · unranked

0 citations

Derek D. Cyr, Miloni Shah, Anne M. Lachiewicz, Andreas Schmid, Martín Maillo +11 more